

# Ontario Public Drug Programs

## Drug Submission Status

---

**Generic Name:** lurasidone HCl

**Brand Name:** Latuda

**Strength:** 20mg and 60mg tablet

**Manufacturer:** Sunovion Pharmaceuticals Canada Inc.

**Indication:** For the management of the manifestations of schizophrenia after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.  
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.

**Rapid Review:** Not requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	21/08/2014	09/10/2014	EO decision rendered	Funding not considered through Ontario Public Drug Programs

### Rapid Review:

Details of the Rapid Review process can be found at:

[www.health.gov.on.ca/en/pro/programs/drugs/drug\\_submissions/rapid\\_review\\_process.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/drug_submissions/rapid_review_process.aspx)

### Review Status:

- Screening – Ministry is screening the manufacturer’s submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.

- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.
- Ontario Steering Committee for Cancer Drugs (OSCCD) review completed-A recommendation was made by the OSCCD.
- Executive Officer (EO) decision rendered.

## Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

[www.health.gov.on.ca/en/pro/programs/drugs/ced\\_rec\\_table.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/ced_rec_table.aspx)

Updated: February 24, 2015